A PYMNTS Company

UK: Pfizer fined by UK regulator amid pricing probe

By  |  April 13, 2016

The UK antitrust regulator has fined Pfizer roughly $14,000 for a “flagrant” violation of rules in connection with a probe into the pricing of an epilepsy medicine.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The move comes amid a heated squabble between Pfizer and the UK Competition and Markets Authority over phenytoin sodium capsules. The drug maker used to market the medicine under the brand name Epanutin, but sold the UK distribution rights to another company, Flynn Pharma, in 2012.

    Pfizer continued to manufacture the drug, but prices began to rise significantly.

    Pfizer suddenly began selling its medicine to Flynn at prices that were between eight and 17 times higher than what the company historically charged, according to the regulator. And Flynn sold the drug to customers at 25 and 27 times what Pfizer had been charging.

    Full Content: Stat News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.